A review of the assessment of antidepressant-induced sexual dysfunction used in randomized, controlled clinical trials

Pharmacopsychiatry

Volumn 40, Issue 5, 2007, Pages 173-182

  Haberfellner, E M ^a,b  

^a Rehabilitation Center for Psychosocial Health   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; DOXEPIN; DULOXETINE; FLUOXETINE; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; REBOXETINE; TRAZODONE; VENLAFAXINE;

CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; REVIEW; SEMI STRUCTURED INTERVIEW; SEXUAL DYSFUNCTION; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 35148817023     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-985881     Document Type: Review

References (48)

1. Baldwin DS. Sexual dysfunction associated with antidepressant drugs. Expert Opin Drug Saf 2004; 3: 457-470
2. Balon R. The effects of antidepressants on human sexuality: Diagnosis and management update 2004. Primary Psychiatry 2004; 11: 58-66
3. Behnke K, Sogaard J, Martin S, Bauml J, Ravindran AV, Agren H et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 2003; 23: 358-364
4. Bonierbale M, Lancon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 2003; 19: 114-124
5. Clayton AH, Owens JE, MacGarvey EL. Assessment of paroxetine induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire. Psychopharmacol Bull 1995; 31: 397-413
6. Clayton AH, MacGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability and validity. Psychopharmacol Bull 1997; 33: 731-745
7. Cohen S, Kühn KU, Bender S, Erfurth A, Gastpar M, Murafi A, Rothermundt M, Signerski J, Sträter B, Teusch L, Weig W, Welling A, Westheide J, Huber TJ. Sexual impairment in psychiatric inpatients: focus on depression. Pharmacopsychiatry 2007; 40: 58-63
8. Cunningham LA, Venlafaxine XR, 208 Study Group. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 1997; 9: 157-164
9. Demyttenaere K, Fruyt J De, Sienaert P. Psychotropics and sexuality. Int Clin Psychopharmacol 1998; 13 (Suppl 6): 35-41
10. Derogatis LR, Maelisaratos N. The DSFI: a multidimensional measure of sexual functioning. J Sex Marital Ther 1979; 5: 244-281
11. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996; 57 (Suppl 2): 53-62
12. Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 2001; 62 (Suppl 3): 22-34
13. Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 2006; 39: 66-75
14. Gelenberg AJ, Trivedi MH, Rush AJ, Thase ME, Howland R, Klein DN et al. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry 2003; 54: 806-817
15. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002; 63: 225-231
16. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24: 389-399
17. Haberfellner EM. Role of receptor binding profiles in antidepressant induced sexual dysfunction. J Clin Psychiatry 2002; 63: 168
18. Haberfellner EM, Rittmannsberger H. Spontanous remission of SSRI-induced orgasm delay. Pharmacopsychiatry 2004; 37: 127-130
19. Harrison WM, Rabkin JG, Ehrhardt AA. Stewart JW et al. Effects of antidepressant medication on sexual function: A controlled study. J Clin Psychopharmacol 1986; 6: 144-149
20. Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics. Pharmacopsychiat 2006; 39: 47-51
21. Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 1999; 56: 201-208
22. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000; 61: 276-281
23. Labbate LA, Lare SB. Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire. Psychother Psychosom 2001; 70: 221-225
24. Landen M, Hogberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. J Clin Psychiatry 2005; 66: 100-106
25. Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. J Psychopharmacol 1997; 11: 72-82
26. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU-side effect rating scale. Acta Psychiatr Scand 1987; 76 (Suppl 334): 1-100
27. MacGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, MacKnight KM et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000; 26: 25-40
28. Mehtonen OP, Sogaard J, Roponen P, Behnke K, Venlafaxine 631 Study Group. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry 2000; 61: 95-100
29. Modell JG, Katholi CR, Modell JD, Palma RL De. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997; 61: 476-487
30. Montejo-González AL, Llorca G, Izquirdo JA, Ledesma A, Bousono M, Calcedo A et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and desriptive clinical study of 344 patients. J Sex Marital Ther 1997; 23: 176-194
31. Montejo AL, Llorca G, Izquirdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001; 62 (Suppl 3): 10-21
32. Montgomery SA, Baldwin DS, Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J Affect Disord 2002; 69: 119-140
33. Muller MJ, Ruof J, Graf-Morgenstern M, Porst H, Benkert O. Quality of partnership in patients with erectile dysfunction after sildenafil treatment. Pharmacopsychiatry 2001; 34: 91-95
34. Musa MN, Staneluis JM. Adverse events of fluoxetine: postmarketing compared with premarketing clinical trials. J Clin Psychiatry 2000; 61: 874
35. Rabkin JG, Markowitz JS, Ocepek-Welikson K, Wager SS. General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. J Clin Psychopharmacol 1992; 12: 3-10
36. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19: 67-85
37. Rothschild AJ. Sexual side effects of antidepressants. J Clin Psychiatry 2000; 61 (Suppl 11): 28-36
38. Taylor MJ, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: Systematic review of randomized controlled trials. J Affect Disord 2005; 88: 241-254
39. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002; 47: 174-180
40. Versiani M, Maehilane L, Gaszner P, Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 1999; 60: 400-406
41. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2002; 20: 28-34
42. Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ, Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005; 19: 137-146
43. Wade A, Crawford GM, Angus M, Wilson R, Hamilton L. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol 2003; 18: 133-141
44. Walker PW, Cole JO, Gardner EA, Hughes AR, Johnston JA, Batey SR et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993; 54: 459-465
45. Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. Acta Psychiatr Scand 2006; 114: 384-397
46. Williams VSL, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HM. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries. A cross-sectional patient survey. J Clin Psychiatry 2006; 67: 204-210
47. Zajecka J, Mitchell S, Fawcett J. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull 1997; 33: 755-760
48. Zajecka J, Dunner DL, Gelenberg AJ, Hirschfeld RM, Kornstein SG, Ninan PT et al. Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. J Clin Psychiatry 2002; 63: 709-716